Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis. J of Skin 2024, 8 (6), s442. https://doi.org/10.25251/skin.8.supp.442.